cephalosporin c has been researched along with rpx7009 in 9 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (11.11) | 24.3611 |
2020's | 8 (88.89) | 2.80 |
Authors | Studies |
---|---|
Ammerman, NC; Kaushik, A; Kreiswirth, BN; Lamichhane, G; Lee, J; Martins, O; Nuermberger, EL; Parrish, NM | 1 |
Millar, BC; Moore, JE; Moore, RE | 1 |
Pregnolato, M; Taccani, M; Terreni, M | 1 |
Belcher, R; Zobell, JT | 1 |
Castanheira, M; Duncan, LR; Mendes, RE; Sader, HS | 1 |
Bianco, G; Boattini, M; Casale, R; Cavallo, R; Comini, S; Costa, C; Iannaccone, M | 1 |
Amadesi, S; Ambretti, S; Gaibani, P; Lazzarotto, T | 1 |
Hsueh, PR; Lee, YL | 1 |
Hsueh, PR; Ko, WC; Lee, YL | 1 |
1 review(s) available for cephalosporin c and rpx7009
Article | Year |
---|---|
New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Boronic Acids; Cefiderocol; Cephalosporins; Chemistry, Pharmaceutical; Clostridioides difficile; Clostridium Infections; Drug Design; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gonorrhea; Humans; Meropenem; Neisseria gonorrhoeae; Nitroimidazoles; Sisomicin; Tetracyclines | 2021 |
8 other study(ies) available for cephalosporin c and rpx7009
Article | Year |
---|---|
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactams; Boronic Acids; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous | 2019 |
Antimicrobial susceptibility of plastic-associated bacteria isolated from the ocean to novel antibiotics (delafloxacin, meropenem/vaborbactam, ceftolozane/tazobactam, ceftobiprole) - Can environmental bacteria be predictors of persistence of antibiotic ac
Topics: Antarctic Regions; Anti-Bacterial Agents; Bacteria; Boronic Acids; Cephalosporins; Drug Resistance, Microbial; Fluoroquinolones; Islands; Meropenem; Oceans and Seas; Plastics; Polystyrenes; Tazobactam | 2020 |
Optimization of antibiotics for cystic fibrosis pulmonary exacerbations due to highly resistant nonlactose fermenting Gram negative bacilli: Meropenem-vaborbactam and cefiderocol.
Topics: Anti-Bacterial Agents; Boronic Acids; Cefiderocol; Cephalosporins; Child; Cystic Fibrosis; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Meropenem | 2021 |
Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Soft Tissue Infections; Tazobactam | 2021 |
Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacterial Proteins; beta-Lactamases; Boronic Acids; Cefiderocol; Ceftazidime; Cephalosporins; COVID-19; Drug Combinations; Humans; Meropenem; Microbial Sensitivity Tests | 2022 |
Genome characterization of a Klebsiella pneumoniae co-producing OXA-181 and KPC-121 resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam and cefiderocol isolated from a critically ill patient.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Cefiderocol; Ceftazidime; Cephalosporins; Critical Illness; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2022 |
Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveil
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Doripenem; Humans; Imipenem; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |